Transfusion Transmitted Infectious Diseases


evaluate and advance safety of blood transfusion by analysing Transfusion Transmitted Infectious Diseases, coordinating international studies and publishing scientific reports

Following blood transfusion, there is a risk of transfusion-transmitted infectious diseases (TTID), despite current advanced screening technologies. Infectious agents involved are very diverse and include hepatitis B (HBV), hepatitis C (HCV), human immunodeficiency (HIV-1/2), human T-cell lymphotropic (HTLV-I/II), Cytomegalo- (CMV), Parvo- B19, West Nile (WNV) and Dengue viruses. Trypanosomiasis, malaria, and Transmissible Spongiform Encephalopathy (TSE) also belong to TTID. TTID can be reduced by donor exclusion, screening for serological infection markers or nucleic acid testing (NAT) by viral gene amplification. Despite this, blood-borne infectious agents are transmitted through transfusion of infected blood donated by apparently healthy and asymptomatic blood donors.


We are responsible for evaluation and promotion of ways to increase blood safety in order to reduce the frequency of TTID. Our members participate in the following subgroups:

1) Bacteria

2) Parasites

3) Virology

4) Prions/Transmissible spongiform encephalopathy (TSE)

5) Surveillance, Risk Assessment & Policy (SRAP)

The latest findings based on literature reviews as well as member's experiences are also discussed. And we bring together scientific experts, company representatives and members from leading institutions and regulatory authorities.

Our Chairperson is Michael Busch.




We participate in subgroups and attend 1-2 day WP meetings linked to ISBT Congresses. Our subgroups develop and execute various surveys and laboratory experiments, analyse data with the intention to publish. Our subgroups discuss issues by conference call and in person. We sponsor Travel Awards and are launching a mentoring and training program for early/mid-career investigators, particularly from resource-limited countries.

Joining the WP

Applicants for membership must have a documented interest in TTID and preferably be involved in TTID surveillance or research. Equal representation of all world regions is a priority; we currently have over 90 members from ~30 different countries.

Employees from pharmaceutical companies are only able to join as Corporate Sponsors.

Interested in joining the TTID WP? Please email the ISBT Office or our Chairperson. 





Some of the content is only accessible for ISBT-members. To join us, click here.

General Presentations



I TRY IT Workshop in Dubai

Participants of the I TRY IT programme were invited to the 34th International Congress of the ISBT in Dubai to attend one-on-one mentoring sessions and to receive training on peer reviewing. 

To read the entire report please login or become an ISBT member.

Cost Utility Analysis Webtool for HIV, HBV and HCV

Access the webtool here.



Michael Busch

Michael Busch


Blood Systems Research Institute
San Francisco, USA

All subgroups have different coordinators, contact details are shown below.